Compare Tango Therapeutics Inc. (TNGX) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while Vanguard Total Stock Market Index Fund ETF trades at $375.54 (market cap $2.30T). The key difference: Vanguard Total Stock Market Index Fund ETF is far larger — about 613.3× Tango Therapeutics Inc.'s market cap, and Vanguard Total Stock Market Index Fund ETF is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Vanguard Total Stock Market Index Fund ETF for 132 Days on average.
| TNGX | VTI | |
|---|---|---|
Market Cap | $3.75B | $2.30T |
Volume | 9,619,106 | 2,460,185 |
Sector | Health | — |
52-Week High | $32.90 | $384.30 |
52-Week Low | $7.50 | $311.68 |
Typical Hold Time | 0 Days | 132 Days |
Enterprise Value | $2.77B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
VTI trades at $381.32, down slightly by 0.07% today, with a bullish technical signal driven by strong moving average alignment. The ETF offers broad U.S. equity exposure, though key financial ratios are not provided in the data. Recent news highlights its appeal for long-term investors seeking diversification and low-cost market access.
The outlook remains positive given strong technical momentum and media optimism, but risks include market concentration in top holdings and broader economic volatility. Investors benefit from VTI's extensive diversification, yet should monitor allocation weights and macroeconomic trends for potential impacts on returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
